Sitrin Capital Management LLC Lowers Position in Eli Lilly and Company $LLY

Sitrin Capital Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 8.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,078 shares of the company’s stock after selling 566 shares during the period. Eli Lilly and Company comprises approximately 2.4% of Sitrin Capital Management LLC’s investment portfolio, making the stock its 25th largest holding. Sitrin Capital Management LLC’s holdings in Eli Lilly and Company were worth $4,738,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its stake in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $54,000. Duquesne Family Office LLC raised its stake in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $570,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. UBS Group reduced their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Guggenheim upped their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $943.00.

Eli Lilly and Company Stock Up 0.2%

Shares of LLY opened at $845.55 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The company has a market capitalization of $800.28 billion, a PE ratio of 55.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The stock has a fifty day simple moving average of $738.69 and a two-hundred day simple moving average of $766.57. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company earned $3.92 EPS. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.